| 000 | 01808 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517095930.0 | ||
| 264 | 0 | _c20170309 | |
| 008 | 201703s 0 0 eng d | ||
| 022 | _a1096-0295 | ||
| 024 | 7 |
_a10.1016/j.yrtph.2016.05.022 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGould, Janet | |
| 245 | 0 | 0 |
_aSpecial endpoint and product specific considerations in pharmaceutical acceptable daily exposure derivation. _h[electronic resource] |
| 260 |
_bRegulatory toxicology and pharmacology : RTP _cAug 2016 |
||
| 300 |
_aS79-93 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aDrug Contamination _xprevention & control |
| 650 | 0 | 4 |
_aDrug Hypersensitivity _ximmunology |
| 650 | 0 | 4 |
_aDrug Industry _xlegislation & jurisprudence |
| 650 | 0 | 4 |
_aDrug-Related Side Effects and Adverse Reactions _ximmunology |
| 650 | 0 | 4 | _aGuidelines as Topic |
| 650 | 0 | 4 | _aHealth Policy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMutagenicity Tests |
| 650 | 0 | 4 | _aNo-Observed-Adverse-Effect Level |
| 650 | 0 | 4 |
_aOccupational Exposure _xadverse effects |
| 650 | 0 | 4 |
_aOccupational Health _xlegislation & jurisprudence |
| 650 | 0 | 4 |
_aPharmaceutical Preparations _xclassification |
| 650 | 0 | 4 | _aPharmacokinetics |
| 650 | 0 | 4 | _aPolicy Making |
| 650 | 0 | 4 |
_aProteins _xadverse effects |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 |
_aToxicity Tests _xmethods |
| 650 | 0 | 4 | _aToxicokinetics |
| 700 | 1 | _aCallis, Courtney M | |
| 700 | 1 | _aDolan, David G | |
| 700 | 1 | _aStanard, Brad | |
| 700 | 1 | _aWeideman, Patricia A | |
| 773 | 0 |
_tRegulatory toxicology and pharmacology : RTP _gvol. 79 Suppl 1 _gp. S79-93 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.yrtph.2016.05.022 _zAvailable from publisher's website |
| 999 |
_c26066558 _d26066558 |
||